<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099058</url>
  </required_header>
  <id_info>
    <org_study_id>M14-237</org_study_id>
    <secondary_id>2014-003154-14</secondary_id>
    <nct_id>NCT02099058</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and
      preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib,
      erlotinib, and nivolumab in subjects with advanced solid tumors likely to express c-Met.
      Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2014</start_date>
  <completion_date type="Anticipated">February 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 9, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time to Cmax (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half life</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as the proportion of the subjects who have a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>PFS is defined as the time from the first dose date of ABBV-399 to either disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DOR is defined as the time from the subject's initial CR or PR to the time of disease progression.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Advanced Solid Tumors Cancer</condition>
  <arm_group>
    <arm_group_label>Arm E (Telisotuzumab vedotin plus Osimertinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin to be evaluated with Osimertinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (Telisotuzumab vedotin plus Nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin to be evaluated with Nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy Telisotuzumab vedotin (21-day dosing cycles)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Telisotuzumab vedotin plus Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin to be evaluated with Erlotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy Telisotuzumab vedotin (28-day dosing cycles)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>It is administered orally everyday.</description>
    <arm_group_label>Arm E (Telisotuzumab vedotin plus Osimertinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>It is an intravenous infusion administered every 14 days.</description>
    <arm_group_label>Arm D (Telisotuzumab vedotin plus Nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telisotuzumab vedotin</intervention_name>
    <description>It is administered by infusion in 21-day dosing cycles.</description>
    <arm_group_label>Arm A (Telisotuzumab vedotin plus Erlotinib)</arm_group_label>
    <arm_group_label>Monotherapy Telisotuzumab vedotin (21-day dosing cycles)</arm_group_label>
    <other_name>ABBV-399</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telisotuzumab vedotin</intervention_name>
    <description>It is administered by infusion in 28-day dosing cycles.</description>
    <arm_group_label>Arm D (Telisotuzumab vedotin plus Nivolumab)</arm_group_label>
    <arm_group_label>Arm E (Telisotuzumab vedotin plus Osimertinib)</arm_group_label>
    <arm_group_label>Monotherapy Telisotuzumab vedotin (28-day dosing cycles)</arm_group_label>
    <other_name>ABBV-399</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>It is administered orally everyday.</description>
    <arm_group_label>Arm A (Telisotuzumab vedotin plus Erlotinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have advanced Non-Small Cell Lung Cancer (NSCLC) that is not amenable
             to surgical resection or other approved therapeutic options that have demonstrated
             clinical benefit.

          -  Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
             to 2.

          -  Participant must have measurable disease per Response Evaluation Criteria In Solid
             Tumors (RECIST) version 1.1.

          -  Participant has fresh and/or archived diagnostic formalin-fixed paraffin embedded
             (FFPE) tumor tissue confirmed available for analyses.

          -  Participant has adequate bone marrow, renal, and hepatic function.

          -  Women of childbearing potential must have a negative serum pregnancy test within 14
             days prior to initiation of treatment.

          -  Participants in the combination therapy arms A and D must be eligible to receive
             erlotinib, or nivolumab per most current prescribing information, or at the discretion
             of the Investigator.

          -  Participants in the combination therapy Arm E must satisfy following criteria.

               -  Participant must have metastatic NSCLC with documented Epidermal Growth Factor
                  Receptor (EGFR) mutation(s) known to be sensitive to osimertinib, including
                  del19, L858R, G719X or L861Q.

               -  Participant must have discontinued osimertinib due to disease progression.

               -  Participant must have available post-progression tumor tissue for central c-Met
                  immunohistochemistry (IHC) testing.

        Exclusion Criteria:

          -  Participant has received anticancer therapy including chemotherapy, radiation therapy,
             immunotherapy, biologic, or any investigational therapy within a period of 21 days or
             herbal therapy within 7 days prior to the first dose of ABBV-399.

          -  Participant has uncontrolled metastases to the central nervous system (CNS) based on
             head CT or MRI. Subjects with brain metastases may be eligible 2 weeks after
             definitive therapy to all known sites of CNS disease provided they are asymptomatic
             and either off or on a non-increasing dose (in last 2 weeks) of systemic steroids and
             not on anticonvulsants for seizure activity directly related to progressive CNS
             metastases.

          -  Participant has history of interstitial lung disease (ILD) or pneumonitis that
             required treatment with systemic steroids, or any evidence of active ILD or
             pneumonitis.

          -  Participant has unresolved clinically significant adverse events &gt;= Grade 2 from prior
             anticancer therapy, except for alopecia or anemia.

          -  Participant has had major surgery within 21 days prior to the first dose of ABBV-399.

          -  Participant has a clinically significant condition(s) described in the protocol.

          -  Participant has history of major immunologic reaction to any Immunoglobulin G (IgG)
             containing agent.

          -  Participants enrolled on the combination therapy phase must satisfy the above
             exclusion criteria and also the following:

          -  Participants may not receive ABBV-399 in combination with osimertinib, erlotinib or
             nivolumab if they have any medical condition which in the opinion of the Investigator
             places the participant at an unacceptably high risk for toxicities from the
             combination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare /ID# 123761</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center /ID# 216836</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope /ID# 153759</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 148295</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine /ID# 165107</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center - Main /ID# 129805</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center /ID# 123759</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 136995</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hosp /ID# 165876</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 129804</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 168782</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 149857</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herbert Herman Cancer Center /ID# 149858</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institut /ID# 217418</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 143798</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 123763</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC /ID# 129802</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research /ID# 123760</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center /ID# 154648</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists /ID# 165708</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen /ID# 170118</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tays Keskussairaala /ID# 165065</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy /ID# 132747</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone /ID# 151570</name>
      <address>
        <city>Marseille CEDEX 05</city>
        <state>Provence-Alpes-Cote-d Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 164077</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 217570</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 217571</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital /ID# 217333</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 217334</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hosp /ID# 217494</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital /ID# 167175</name>
      <address>
        <city>Tainan City</city>
        <state>Tainan</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 167173</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hosp /ID# 217392</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

